Options
Human parvovirus B19 VP1uāinduced osteoclastogenesis is enhanced by RANKL in RAW264.7 macrophage cells
Journal
Molecular Medicine Reports
Date Issued
2026-09-01
Author(s)
Abstract
Human parvovirus B19 (B19V) DNA and antigens are frequently detected in synovial tissue; however, the mechaā nisms linking B19V infection to bone destruction remain unclear. The present study investigated the B19V VP1 unique region (VP1u) and its influence on osteoclast differentiaā tion. RAW264.7 macrophages were cultured with or without receptor activator of NFāĪŗB ligand (RANKL) and B19VāVP1u for up to 7 days. Tartrateāresistant acid phosphatase staining, bone resorption assays and western blotting were used to assess osteoclastogenesis. The involvement of signaling pathways was investigated using an antiāTNFāα antibody, and inhibitors of MAPK, ERK, JNK and NFāĪŗB signaling. B19VāVP1u alone induced osteoclastogenesis in a doseā and timeādependent manner and, in the presence of RANKL, further increased osteoclast size and number. B19VāVP1u significantly increased pit resorption, and nuclear factor of activated T cells (NFAT)2 (also known as NFATc1), cathepsin K, cāFOS, MMP9 and dendritic cellāspecific transmembrane protein expression. The inhibition of ERK, JNK, NFāĪŗB or TNFāα did not alter the effects of VP1u, whereas blockade of p38 MAPK nearly abolished VP1uāinduced osteoclastogenesis. These findings indicate that B19VāVP1u acts as a strong osteoclastogenic factor through a p38ādependent but TNFāαāindependent pathway in vitro. The present study supports a dual mechanism of B19Vāinduced bone pathology, whereby VP1u directly promotes osteoclastogenesis, whereas inflammation mediā ates bone resorption via cytokine signaling. Targeting viral proteināhost signaling interactions may offer novel therapeutic approaches for B19Vāassociated bone erosion.
Type
journal article